Drugs / HR19006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05788588 | Apr → Nov 2023 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR19006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05788588 ↗ |
| Route | Intravenous | “administered via a central venous line” NCT05788588 ↗ |